Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | May 24, 2017 | May 25, 2017 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director · CHAIRMAN & CEO | September 01, 2026 | September 03, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 08, 2017 | September 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date May 24, 2017 · Filed May 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2027-05-24 | Direct | 30,000 |
Reported balance
After 2017-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-24 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning June 24, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning June 24, 2017.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 86,165 |
Reported balance
After 2026-09-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-01 · Exercise / conversion · Acquired 9,991 · Balance 86,165 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,646 |
Reported balance
After 2026-09-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-01 · Exercise / conversion · Acquired 6,481 · Balance 92,646 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 98,883 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Acquired 6,237 · Balance 98,883 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 107,492 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Exercise / conversion · Acquired 8,609 · Balance 107,492 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,348 |
Reported balance
After 2026-09-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-01 · Tax withholding · Disposed 15,144 · Balance 92,348 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 30,050 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 30,050 · Balance 30,050 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 25,826 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 8,609 · Balance 25,826 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 12,475 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 6,237 · Balance 12,475 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,481 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 6,481 · Balance 6,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 9,991 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 120,150 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 120,150 · Balance 120,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 | 109,795 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 109,795 |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 | 51,794 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 51,794 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Syros Pharmaceuticals, Inc.
Report date June 08, 2017 · Filed September 22, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2027-06-07 | Direct | 11,000 |
Reported balance
After 2017-06-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 11,000 · Balance 11,000 F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.
F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · derivative · entry 13 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 9,991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · derivative · entry 12 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,481 Underlying: Class A Ordinary Share · 6,481 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · derivative · entry 11 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,475 Underlying: Class A Ordinary Shares · 6,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 8,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,826 Underlying: Class A Ordinary Share · 8,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 120,150 | $0.00 Strike: $79.28 | $0.00 |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,150 Underlying: Class A Ordinary Share · 120,150 shares Expires 2036-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 30,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,050 Underlying: Class A Ordinary Share · 30,050 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 15,144 | $79.28 | $1,200,616.32 |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 92,348 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 107,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 98,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 92,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000016 · form4-09032026_080911.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 86,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · derivative · entry 13 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 9,991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · derivative · entry 12 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,481 Underlying: Class A Ordinary Share · 6,481 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · derivative · entry 11 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,475 Underlying: Class A Ordinary Shares · 6,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 8,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,826 Underlying: Class A Ordinary Share · 8,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 120,150 | $0.00 Strike: $79.28 | $0.00 |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,150 Underlying: Class A Ordinary Share · 120,150 shares Expires 2036-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 30,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,050 Underlying: Class A Ordinary Share · 30,050 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 15,144 | $79.28 | $1,200,616.32 |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 92,348 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 107,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 98,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 92,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000014 · form4-09032026_080914.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 86,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionClass B Ordinary Shares · Derivative | 900,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000012 · form4-06022026_080657.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · The Anglia 2013 Revocable Trust Disclosed balance after: 626,160 Underlying: Class A Ordinary Share · 900,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Ordinary Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Ordinary Shares or one share of Class B1 Ordinary Shares and will automatically convert into Class A Ordinary Shares upon transfer to an unaffiliated party. F1 · derivative.exercise_date: Each share of Class B Ordinary Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Ordinary Shares or one share of Class B1 Ordinary Shares and will automatically convert into Class A Ordinary Shares upon transfer to an unaffiliated party. F1 · derivative.expiration_date: Each share of Class B Ordinary Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Ordinary Shares or one share of Class B1 Ordinary Shares and will automatically convert into Class A Ordinary Shares upon transfer to an unaffiliated party. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionClass A Ordinary Share | 900,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000012 · form4-06022026_080657.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · The Anglia 2013 Revocable Trust Disclosed balance after: 951,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Ordinary Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Ordinary Shares or one share of Class B1 Ordinary Shares and will automatically convert into Class A Ordinary Shares upon transfer to an unaffiliated party. Read SEC document |
| May 01, 2026 Filed May 1, 2026 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 48,565 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001532218-26-000008 · form4-05012026_080517.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 48,565 shares Expires 2028-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 01, 2026 Filed May 1, 2026 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 48,565 | $54.02 | $2,623,481.30 |
DisclosureSEC source: 0001532218-26-000008 · form4-05012026_080517.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.155. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 01, 2026 Filed May 1, 2026 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 48,565 | $30.93 | $1,502,115.45 |
DisclosureSEC source: 0001532218-26-000008 · form4-05012026_080517.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,141 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · derivative · entry 17 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,565 Underlying: Class A Ordinary Share · 2,141 shares Expires 2028-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 2,141 | $54.01 | $115,635.41 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,141 | $30.93 | $66,221.13 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 22,544 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · derivative · entry 16 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,706 Underlying: Class A Ordinary Share · 22,544 shares Expires 2028-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 22,544 | $54.01 | $1,217,601.44 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.225. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 22,544 | $30.93 | $697,285.92 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 51,750 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · derivative · entry 15 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,250 Underlying: Class A Ordinary Share · 51,750 shares Expires 2028-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 431,904 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · derivative · entry 14 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 431,904 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 51,750 | $54.02 | $2,795,535.00 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 243,596 | $52.02 | $12,671,863.92 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,750 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $52.00 and $52.58. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 113,673 | $51.47 | $5,850,749.31 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 295,346 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $51.00 and $51.99. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 74,635 | $50.43 | $3,763,843.05 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,019 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.985. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 51,750 | $30.93 | $1,600,627.50 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 483,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 431,904 | $10.36 | $4,474,525.44 |
DisclosureSEC source: 0001532218-26-000006 · form4-04302026_100400.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000004 · form4-04082026_080403.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 9,991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 4,831 | $48.94 | $236,429.14 |
DisclosureSEC source: 0001532218-26-000004 · form4-04082026_080403.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 76,174 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000004 · form4-04082026_080403.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 81,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 7,278 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001532218-26-000004 · form4-04082026_080403.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,904 Underlying: Class A Ordinary Share · 7,278 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 7,278 | $50.01 | $363,972.78 |
DisclosureSEC source: 0001532218-26-000004 · form4-04082026_080403.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.005 and $50.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 7,278 | $10.36 | $75,400.08 |
DisclosureSEC source: 0001532218-26-000004 · form4-04082026_080403.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 8,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,826 Underlying: Class A Ordinary Share · 8,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,475 Underlying: Class A Ordinary Share · 6,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,481 Underlying: Class A Ordinary Share · 6,481 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.